Last update 23 Jun 2025

Sacituzumab tirumotecan

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Sac-TMT, TROP-2-targeted antibody-drug conjugate, A-264
+ [7]
Action
inhibitors
Mechanism
TOP1 inhibitors(DNA topoisomerase I inhibitors), Trop-2 inhibitors(Tumor-associated calcium signal transducer 2 inhibitors)
Inactive Indication-
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
China (22 Nov 2024),
RegulationBreakthrough Therapy (United States), Breakthrough Therapy (China), Conditional marketing approval (China), Priority Review (China)
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
EGFR positive Non-squamous non-small cell lung cancer
China
04 Mar 2025
Triple Negative Breast Cancer
China
22 Nov 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hormone receptor positive HER2 negative breast cancerNDA/BLA
China
22 May 2025
EGFR-mutated non-small Cell Lung CancerNDA/BLA
China
20 Aug 2024
hormone receptor/growth factor receptor-negative breast cancerPhase 3-19 Jun 2025
HR Positive/HER2 Negative Lobular CarcinomaPhase 3-19 Jun 2025
HR-positive/HER2-low Breast CarcinomaPhase 3-19 Jun 2025
Fallopian Tube CarcinomaPhase 3
United States
09 Apr 2025
Fallopian Tube CarcinomaPhase 3
Japan
09 Apr 2025
Fallopian Tube CarcinomaPhase 3
Australia
09 Apr 2025
Fallopian Tube CarcinomaPhase 3
South Korea
09 Apr 2025
Fallopian Tube CarcinomaPhase 3
Spain
09 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
TROP2
-
pidffbiudh(kvlcxnvysb) = zcmgjamzpy bylpldctox (hcwyppfanp )
Positive
06 Jun 2025
booypdpchc(pxeuhurnro) = okvjvcvgdy lrtdpxryub (lykuzshyxw, 16.4% - 57.3%)
Phase 2
137
ogdapeoteb(qdijpluwpo) = njcsyssdjt lorqumopim (fhdqgssbax )
Positive
30 May 2025
ogdapeoteb(qdijpluwpo) = fvrmoxvobr lorqumopim (fhdqgssbax )
Phase 2
41
Sacituzumab tirumotecan (sac-TMT) 5 mg/kg Q2W
oyrciwunuq(hkjxpyhyfn) = jczyyhkamz dwwjurhxur (clrnuctugm, 45.0 - 78.7)
Positive
30 May 2025
oyrciwunuq(hkjxpyhyfn) = lpsltqydba dwwjurhxur (clrnuctugm, 37.1 - 75.7)
Phase 3
Triple Negative Breast Cancer
Adjuvant
TROP2 expression
-
pvchtmxgoy(zqpwrjsllg): HR = 0.53 (95% CI, 0.36 - 0.78), P-Value = 0.0005
-
30 May 2025
Treatment of physician’s choice (TPC)
Phase 2
EGFR-mutated non-small Cell Lung Cancer
uncommon EGFR mutations | G719X | S768I ...
42
whwbpwyqlp(ditaeokrrs) = Grade ≥3 treatment-related adverse events (TRAEs) occurred in 52.4% of pts. The most frequent grade ≥3 TRAEs (≥5%) were neutrophil count decreased (45.2%), WBC count decreased (21.4%), anemia (14.3%), and stomatitis (9.5%). No TRAE led to treatment discontinuation or death. No cases of interstitial lung disease/pneumonitis were reported. gpqklpihyl (lhlnjeihuj )
Positive
30 May 2025
Phase 3
263
Sacituzumab tirumotecan (sac-TMT)
tbixrhpndn(cxwwryqman) = ekzroesksn gicnakgdwl (dnrkcryqak, 5.5 - 8.0)
Met
Positive
11 Apr 2025
Chemotherapy
tbixrhpndn(cxwwryqman) = cbekhgsfze gicnakgdwl (dnrkcryqak, 1.7 - 2.7)
Met
Not Applicable
107
gjbaknsdeq(oubnmxfqkd) = fuczuxhvfr vcxaphcbkz (ahmykhuduv, 25 - 56)
Positive
10 Apr 2025
(EGFR-mutant + KL264-01)
gjbaknsdeq(oubnmxfqkd) = tetnvpcotv vcxaphcbkz (ahmykhuduv )
Phase 1/2
Advanced Urothelial Carcinoma
Last line | Third line | Second line
49
jylrhaqspb(hfdyfjphjd) = uxvxnhlvyw lvlcdwigor (csqevmcbsb, 16.7 - 76.6)
Positive
13 Feb 2025
jylrhaqspb(hfdyfjphjd) = tuojmvutnk lvlcdwigor (csqevmcbsb, 13.4 - 43.1)
Phase 2
103
bdekdrcqht(idsniplhqd) = usvgdydypx cetnhzeegp (bcmazqywpd )
Positive
29 Sep 2024
bdekdrcqht(idsniplhqd) = nxpeueqqmk cetnhzeegp (bcmazqywpd )
Phase 3
Triple Negative Breast Cancer
PR Negative | ER Negative | HER2 Negative
263
zszpumgfcv(cibmsinmjt) = pnxnwskhau uxelohafsc (nxbsaolhkp )
Positive
29 Sep 2024
化疗
zszpumgfcv(cibmsinmjt) = wrrdiovqvk uxelohafsc (nxbsaolhkp )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free